Similar Piperacillin/Tazobactam Target Attainment in Obese versus Nonobese Patients despite Differences in Interstitial Tissue Fluid Pharmacokinetics.
obesity
piperacillin/tazobactam
target-site
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
31 Aug 2021
31 Aug 2021
Historique:
received:
10
07
2021
revised:
09
08
2021
accepted:
27
08
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Precision dosing of piperacillin/tazobactam in obese patients is compromised by sparse information on target-site exposure. We aimed to evaluate the appropriateness of current and alternative piperacillin/tazobactam dosages in obese and nonobese patients. Based on a prospective, controlled clinical trial in 30 surgery patients (15 obese/15 nonobese; 0.5-h infusion of 4 g/0.5 g piperacillin/tazobactam), piperacillin pharmacokinetics were characterized in plasma and at target-site (interstitial fluid of subcutaneous adipose tissue) via population analysis. Thereafter, multiple 3-4-times daily piperacillin/tazobactam short-term/prolonged (recommended by EUCAST) and continuous infusions were evaluated by simulation. Adequacy of therapy was assessed by probability of pharmacokinetic/pharmacodynamic target-attainment (PTA ≥ 90%) based on time unbound piperacillin concentrations exceed the minimum inhibitory concentration (MIC) during 24 h (%
Identifiants
pubmed: 34575456
pii: pharmaceutics13091380
doi: 10.3390/pharmaceutics13091380
pmc: PMC8464843
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Freie Universität Berlin
ID : Open Access Funding
Organisme : Bundesministerium für Bildung, Wissenschaft und Forschung
ID : 01E01001
Références
Clin Ther. 2009 Nov;31(11):2765-78
pubmed: 20110018
Pharmacotherapy. 2017 Nov;37(11):1415-1431
pubmed: 28869666
Clin Microbiol Rev. 2010 Jan;23(1):160-201
pubmed: 20065329
J Antimicrob Chemother. 2014 May;69(5):1416-23
pubmed: 24443514
Pharmacotherapy. 2014 Jan;34(1):28-35
pubmed: 23864417
Clin Pharmacokinet. 2014 Aug;53(8):753-62
pubmed: 24989061
Contemp Clin Trials Commun. 2019 May 10;15:100375
pubmed: 31193565
Clin Pharmacokinet. 2005;44(10):1051-65
pubmed: 16176118
Clin Ther. 2010 Apr;32(4):766-79
pubmed: 20435246
Antimicrob Agents Chemother. 1994 May;38(5):931-6
pubmed: 8067772
NCHS Data Brief. 2020 Feb;(360):1-8
pubmed: 32487284
Eur J Pharm Sci. 2021 Feb 1;157:105607
pubmed: 33141034
Antimicrob Agents Chemother. 2012 Dec;56(12):6343-8
pubmed: 23045356
CPT Pharmacometrics Syst Pharmacol. 2018 Dec;7(12):785-787
pubmed: 30255663
Eur J Pharm Sci. 2017 Nov 15;109S:S59-S64
pubmed: 28552478
Annu Rev Pharmacol Toxicol. 2008;48:303-32
pubmed: 17914927
J Clin Pharmacol. 2015 Aug;55(8):899-908
pubmed: 25823963
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 28052849
N Engl J Med. 2019 Dec 19;381(25):2440-2450
pubmed: 31851800
J Pharmacokinet Pharmacodyn. 2008 Apr;35(2):185-202
pubmed: 18197467
Int J Antimicrob Agents. 2016 Apr;47(4):259-68
pubmed: 26988339
J Pharm Pharmacol. 2019 Dec;71(12):1792-1799
pubmed: 31579949
Arch Intern Med. 2000 Nov 13;160(20):3082-8
pubmed: 11074737
Antimicrob Agents Chemother. 2017 Sep 22;61(10):
pubmed: 28760900
Perit Dial Int. 2004 Jul-Aug;24(4):340-6
pubmed: 15335147
Eur J Pharm Sci. 2019 Jan 15;127:252-260
pubmed: 30391402
Pharm Res. 2021 Mar;38(3):381-395
pubmed: 33723793
Pharmacotherapy. 2006 Sep;26(9):1320-32
pubmed: 16945055
CPT Pharmacometrics Syst Pharmacol. 2012 Sep 26;1:e4
pubmed: 23835884
Metabolism. 2006 Apr;55(4):515-24
pubmed: 16546483
Pharmacotherapy. 2012 Jul;32(7):604-12
pubmed: 22576791
J Antimicrob Chemother. 2005 May;55(5):601-7
pubmed: 15772142
Clin J Am Soc Nephrol. 2015 Mar 6;10(3):382-9
pubmed: 25568216
Crit Care. 2019 Mar 29;23(1):104
pubmed: 30925922
Int J Antimicrob Agents. 2019 Sep;54(3):309-317
pubmed: 31229669
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Int J Antimicrob Agents. 2013 Jan;41(1):52-6
pubmed: 23228881
Clin Microbiol Infect. 2020 Sep;26(9):1222-1228
pubmed: 32311473
Nat Rev Endocrinol. 2019 May;15(5):288-298
pubmed: 30814686
Clin Pharmacol Ther. 2021 Jan;109(1):29-36
pubmed: 33068303
Acta Obstet Gynecol Scand. 2004 Dec;83(12):1202-7
pubmed: 15548157
Antimicrob Agents Chemother. 2013 Feb;57(2):708-15
pubmed: 23147743
BMC Nephrol. 2016 Nov 10;17(1):172
pubmed: 27832768
J Neurosurg. 2003 Mar;98(2 Suppl):149-55
pubmed: 12650399
J Antimicrob Chemother. 2019 Aug 1;74(8):2335-2340
pubmed: 31086958
N Engl J Med. 1987 Oct 22;317(17):1098
pubmed: 3657876
Crit Care Med. 2017 May;45(5):e470-e478
pubmed: 28240688
Am J Kidney Dis. 2013 Aug;62(2):245-52
pubmed: 23566637
Clin Pharmacokinet. 2018 Aug;57(8):989-1000
pubmed: 29080937
Expert Rev Anti Infect Ther. 2007 Jun;5(3):365-83
pubmed: 17547502
J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):365-405
pubmed: 20661651
Adv Chronic Kidney Dis. 2010 Sep;17(5):e53-62
pubmed: 20727504
J Antimicrob Chemother. 2001 Aug;48(2):259-67
pubmed: 11481298
Expert Rev Anti Infect Ther. 2007 Apr;5(2):255-70
pubmed: 17402840
Antibiotics (Basel). 2020 Dec 21;9(12):
pubmed: 33371322
Eur J Pharm Sci. 2005 May;25(1):1-24
pubmed: 15854796
Pharm Res. 2004 Sep;21(9):1698-707
pubmed: 15497699